G1 Therapeutics (GTHX) Stock Price Soars to $1.63 on November 2

G1 Therapeutics (GTHX) Stock Price

On November 2, 2023, G1 Therapeutics (GTHX) stock exhibited remarkable strength, closing at $1.63, marking an impressive daily increase of $0.29, which equated to a substantial 21.64% surge from the previous day's closing price. 

G1 Therapeutics (GTHX) Stock Analysis

On November 2, 2023, G1 Therapeutics (GTHX) witnessed a remarkable surge in its stock price on the NASDAQ. The stock opened at $1.32 and displayed impressive strength throughout the trading session, ultimately closing at $1.63, reflecting a substantial daily gain of $0.29, equivalent to a remarkable 21.64% increase from the previous day's closing price of $1.34.

G1 Therapeutics experienced notable volatility during the day, with the closing price marking a significant upturn. In after-hours trading, GTHX's value was $1.53, indicating a modest decline of 6.13% or $0.10.

G1 Therapeutics' stock also demonstrated substantial variations over the past 52 weeks, with a high of $9.22 and a low of $1.08. The company's market capitalization stood at approximately $84.35 million, underscoring its presence in the biotechnology sector. Notably, G1 Therapeutics did not have a specified price-to-earnings (P/E) ratio or dividend yield.

The impressive performance of GTHX on November 2 marked a day of significant gains, attracting attention from investors in the pharmaceutical and biotechnology sectors as the stock surged with notable momentum.

G1 Therapeutics (GTHX)-Key Data

G1 Therapeutics (GTHX)

G1 Therapeutics is a biopharmaceutical company based in Research Triangle Park, North Carolina, with a primary focus on the development and commercialization of small molecule therapeutics aimed at improving the lives of cancer patients.

As part of its mission, the company is dedicated to advancing innovative treatments and therapies to address the unique needs of individuals battling cancer, contributing to the ongoing efforts in the field of oncology.